Indolent B-Cell Lymphomas: Clinical Application of New Advances in Community Practice

Learn current and novel best-practice strategies for the treatment of patients with marginal zone and follicular lymphomas based on molecular profiling and clinical data in these interactive, expert led 1-hour workshops

To Register: On the Event Dates page click a date/time, click blue Register button in upper right-hand corner. Once registered, you will receive a reminder email with a link to join in advance of the Webinar.



  • Program Overview
  • Marginal Zone Lymphoma
    • Prognostic and Predictive Biomarkers
    • Selecting Treatments
    • Key Safety Considerations
    • Future Directions: Clinical Trials
  • Follicular Lymphoma
    • Prognostic and Predictive Biomarkers
    • Selecting Treatments
    • Key Safety Considerations
    • Future Directions: Clinical Trials
  • Closing Remarks and Question and Answer Session


Date / Time
Event Details


Program Director
Elizabeth Brém, MD

Associate Professor of Medicine
Division of Hematology/Oncology
Department of Medicine
School of Medicine
University of California Irvine Medical Center
Orange, California

Program Director
Christopher R. Flowers, MD, MS

Department Chair, Department of Lymphoma/Myeloma
Division of Cancer Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Paul Barr, MD

Goal Statement
The goal of this program is to improve the knowledge, confidence, and competence of learners in selecting individualized treatments for patients with indolent B-cell lymphomas.

Target Audience
This program is intended for hematologists, medical oncologists, nurses, pharmacists, and other healthcare professionals who treat and manage patients with indolent B-cell lymphomas.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Order and interpret molecular profiling for appropriate patients with indolent B-cell lymphoma to guide therapy selection
  • Select treatment regimens for patients with MZL and FL based on available clinical data, disease characteristics, and individual patient goals and preferences to optimize clinical outcomes
  • Identify patients with indolent B-cell lymphoma who would likely benefit from enrollment on a clinical trial
  • Mitigate, monitor, and manage adverse events associated with newer therapeutic regimens used in the treatment of indolent B-cell lymphomas


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Designation of Credit

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-059-L01-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.